Journal article
Racial differences in systemic immune parameters in individuals with lung cancer
JTO clinical and research reports, Vol.6(1), 100751
01/2025
DOI: 10.1016/j.jtocrr.2024.100751
PMCID: PMC11605181
PMID: 39619775
Abstract
Racial and ethnic disparities in the presentation and outcomes of lung cancer are widely known. To evaluate potential factors contributing to these observations, we measured systemic immune parameters in Black and White patients with lung cancer.
Patients scheduled to receive cancer immunotherapy were enrolled in a multi-institutional prospective biospecimen collection registry. Clinical and demographic information were obtained from electronic medical records. Pre-treatment peripheral blood samples were collected and analyzed for cytokines using a multiplex panel and for immune cell populations using mass cytometry. Differences between Black and White patients were determined and corrected for multiple comparisons.
A total of 187 patients with non-small cell lung cancer (Black, 19; White, 168) were included in the analysis. Compared to White patients, Black patients had greater comorbidity (median Charlson Comorbidity Index 5 vs. 3; P=0.04) and were more likely to have received prior chemotherapy (79% vs. 47%; P=0.03). Black patients had significantly lower levels of CCL23 and CCL27, and significantly higher levels of CCL8, CXCL1, CCL26, CCL25, CCL1, IL-1b, CXCL16, and IFN-γ (all P<0.05, FDR<0.1). Black patients also exhibited greater populations of non-classical CD16+ monocytes, NKT-like cells, CD4+ cells, CD38+ monocytes, and CD57+ gamma delta T cells (all P<0.05).
Black and White patients with lung cancer exhibit several differences in immune parameters, with Black patients exhibiting greater levels of numerous pro-inflammatory cytokines and cell populations. The etiology and clinical significance of these differences warrant further evaluation.
Details
- Title: Subtitle
- Racial differences in systemic immune parameters in individuals with lung cancer
- Creators
- Mitchell S. von Itzstein - The University of Texas Southwestern Medical CenterJialiang Liu - The University of Texas Southwestern Medical CenterHong Mu-Mosley - The University of Texas Southwestern Medical CenterFarjana Fattah - The University of Texas Southwestern Medical CenterJason Y. Park - The University of Texas Southwestern Medical CenterJeffrey A. SoRelle - The University of Texas Southwestern Medical CenterJ. David Farrar - The University of Texas Southwestern Medical CenterMary E. Gwin - The University of Texas Southwestern Medical CenterDavid Hsiehchen - The University of Texas Southwestern Medical CenterYvonne Gloria-McCutchen - The University of Texas Southwestern Medical CenterEdward K. Wakeland - The University of Texas Southwestern Medical CenterSuzanne Cole - The University of Texas Southwestern Medical CenterSheena Bhalla - The University of Texas Southwestern Medical CenterRadhika Kainthla - The University of Texas Southwestern Medical CenterIgor Puzanov - Roswell Park Comprehensive Cancer CenterBenjamin Switzer - Roswell Park Comprehensive Cancer CenterGregory A. Daniels - University of California San DiegoYousef Zakharia - University of IowaMontaser Shaheen - The University of Texas at San Antonio Health Science CenterJianjun Zhang - The University of Texas MD Anderson Cancer CenterYang Xie - The University of Texas Southwestern Medical CenterDavid E. Gerber - The University of Texas Southwestern Medical Center
- Resource Type
- Journal article
- Publication Details
- JTO clinical and research reports, Vol.6(1), 100751
- DOI
- 10.1016/j.jtocrr.2024.100751
- PMID
- 39619775
- PMCID
- PMC11605181
- NLM abbreviation
- JTO Clin Res Rep
- ISSN
- 2666-3643
- eISSN
- 2666-3643
- Publisher
- Elsevier Inc; AMSTERDAM
- Grant note
- National Institute of Allergy and Infectious Disease: 1U01AI156189-01 American Cancer Society-Melanoma Research Alliance Team Award: MRAT-18-114-01-LIB V Foundation Robin Roberts Cancer Survivorship Award: DT2019-007 Burroughs Wellcome Fund: 1P30 CA 142543-03 University of Texas Lung Cancer Specialized Program of Research Excellence (SPORE): P50CA070907-21 University of Texas Stimulating Access to Research in Residency (UT-StARR): R38HL150214 Harold C. Simmons Comprehensive Cancer Center Data Sciences Shared Resource and Biomarker Research Core
This work is funded in part by the National Institute of Allergy and Infectious Disease (1U01AI156189-01; to Drs. Gerber, Wakeland, and Xie) , an American Cancer Society-Melanoma Research Alliance Team Award (MRAT-18-114-01-LIB; to Dr. Gerber) , a V Foundation Robin Roberts Cancer Survivorship Award (DT2019-007; to Dr. Gerber) , a Physician-Scientist Institutional Award from the Burroughs Wellcome Fund (to Dr. von Itzstein) , the University of Texas Lung Cancer Specialized Program of Research Excellence (SPORE) (P50CA070907-21) , the University of Texas Stimulating Access to Research in Residency (UT-StARR, R38HL150214 to Dr. Gwin) , and the Harold C. Simmons Comprehensive Cancer Center Data Sciences Shared Resource and Biomarker Research Core (1P30 CA 142543-03) . The funders were not involved in the study design, conduct, or reporting.
- Language
- English
- Electronic publication date
- 10/2024
- Date published
- 01/2025
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984738390402771
Metrics
2 Record Views